Literature DB >> 18414400

Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction.

M J Christie1.   

Abstract

A large range of neuroadaptations develop in response to chronic opioid exposure and these are thought to be more or less critical for expression of the major features of opioid addiction: tolerance, withdrawal and processes that may contribute to compulsive use and relapse. This review considers these adaptations at different levels of organization in the nervous system including tolerance at the mu-opioid receptor itself, cellular tolerance and withdrawal in opioid-sensitive neurons, systems tolerance and withdrawal in opioid-sensitive nerve networks, as well as synaptic plasticity in opioid sensitive nerve networks. Receptor tolerance appears to involve enhancement of mechanisms of receptor regulation, including desensitization and internalization. Adaptations causing cellular tolerance are more complex but several important processes have been identified including upregulation of cAMP/PKA and cAMP response element-binding signalling and perhaps the mitogen activated PK cascades in opioid sensitive neurons that might not only influence tolerance and withdrawal but also synaptic plasticity during cycles of intoxication and withdrawal. The potential complexity of network, or systems adaptations that interact with opioid-sensitive neurons is great but some candidate neuropeptide systems that interact with mu-opioid sensitive neurons may play a role in tolerance and withdrawal, as might activation of glial signalling. Implication of synaptic forms of learning such as long term potentiation and long term depression in opioid addiction is still in its infancy but this ultimately has the potential to identify specific synapses that contribute to compulsive use and relapse.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18414400      PMCID: PMC2442443          DOI: 10.1038/bjp.2008.100

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  118 in total

Review 1.  Opioids: cellular mechanisms of tolerance and physical dependence.

Authors:  Chris P Bailey; Mark Connor
Journal:  Curr Opin Pharmacol       Date:  2005-02       Impact factor: 5.547

Review 2.  Drug addiction: pathways to the disease and pathophysiological perspectives.

Authors:  Michel Le Moal; George F Koob
Journal:  Eur Neuropsychopharmacol       Date:  2006-12-12       Impact factor: 4.600

3.  Phosphorylation of Galphas influences its association with the micro-opioid receptor and is modulated by long-term morphine exposure.

Authors:  Sumita Chakrabarti; Alan R Gintzler
Journal:  Mol Pharmacol       Date:  2007-06-18       Impact factor: 4.436

4.  Should we be reluctant to prescribe opioids for chronic non-malignant pain?

Authors:  Howard L Fields
Journal:  Pain       Date:  2007-04-20       Impact factor: 6.961

5.  Rapid synthesis and synaptic insertion of GluR2 for mGluR-LTD in the ventral tegmental area.

Authors:  Manuel Mameli; Bénédicte Balland; Rafael Luján; Christian Lüscher
Journal:  Science       Date:  2007-07-27       Impact factor: 47.728

6.  Prescription drug abuse rises globally.

Authors:  Bridget M Kuehn
Journal:  JAMA       Date:  2007-03-28       Impact factor: 56.272

Review 7.  Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities.

Authors:  Wolfgang Sadée; Danxin Wang; Edward J Bilsky
Journal:  Life Sci       Date:  2004-12-08       Impact factor: 5.037

8.  Beta-arrestin2 and c-Src regulate the constitutive activity and recycling of mu opioid receptors in dorsal root ganglion neurons.

Authors:  Wendy Walwyn; Christopher J Evans; Tim G Hales
Journal:  J Neurosci       Date:  2007-05-09       Impact factor: 6.167

Review 9.  Opioid dependence and addiction during opioid treatment of chronic pain.

Authors:  Jane C Ballantyne; Steven K LaForge
Journal:  Pain       Date:  2007-05-04       Impact factor: 6.961

10.  Opioids block long-term potentiation of inhibitory synapses.

Authors:  Fereshteh S Nugent; Esther C Penick; Julie A Kauer
Journal:  Nature       Date:  2007-04-26       Impact factor: 49.962

View more
  144 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

2.  Chronic methadone treatment shows a better cost/benefit ratio than chronic morphine in mice.

Authors:  Johan Enquist; Madeline Ferwerda; Laura Milan-Lobo; Jennifer L Whistler
Journal:  J Pharmacol Exp Ther       Date:  2011-11-07       Impact factor: 4.030

3.  μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization.

Authors:  Jamie McPherson; Guadalupe Rivero; Myma Baptist; Javier Llorente; Suleiman Al-Sabah; Cornelius Krasel; William L Dewey; Chris P Bailey; Elizabeth M Rosethorne; Steven J Charlton; Graeme Henderson; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2010-07-20       Impact factor: 4.436

Review 4.  Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction.

Authors:  M Foster Olive
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

5.  Agonists at the δ-opioid receptor modify the binding of µ-receptor agonists to the µ-δ receptor hetero-oligomer.

Authors:  N Kabli; N Martin; T Fan; T Nguyen; A Hasbi; G Balboni; B F O'Dowd; S R George
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 6.  Opioid-induced central immune signaling: implications for opioid analgesia.

Authors:  Peter M Grace; Steven F Maier; Linda R Watkins
Journal:  Headache       Date:  2015-03-31       Impact factor: 5.887

7.  Long-term morphine delivery via slow release morphine pellets or osmotic pumps: Plasma concentration, analgesia, and naloxone-precipitated withdrawal.

Authors:  Virginia D McLane; Ivy Bergquist; James Cormier; Deborah J Barlow; Karen L Houseknecht; Edward J Bilsky; Ling Cao
Journal:  Life Sci       Date:  2017-07-16       Impact factor: 5.037

8.  Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; Abdulmajeed M Jali; Bharath Peddibhotla; Dwight A Williams; Chuanchun Zou; David L Stevens; William L Dewey; Hamid I Akbarali; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2019-01-11       Impact factor: 7.446

Review 9.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

10.  Prior exposure to repeated morphine potentiates mechanical allodynia induced by peripheral inflammation and neuropathy.

Authors:  Lisa C Loram; Peter M Grace; Keith A Strand; Frederick R Taylor; Amanda Ellis; Debra Berkelhammer; Melissa Bowlin; Bryce Skarda; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2012-08-10       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.